Close

mRNA

NIH launches clinical trial of three mRNA HIV vaccines

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines. NIAID is sponsoring the study, called HVTN 302, […]

Read More

COVID19 Antibodies Improve for Months After mRNA Vaccine

Antibodies induced by mRNA COVID-19 vaccines keep improving in quality for at least six months while the immune system continues to “train” its antibody-producing B cells, according to a new study. After vaccination, some B cells become short-lived antibody-producing cells, while others join germinal centers in lymph nodes – essentially, […]

Read More
Translate »